In the wake of an unfavorable advisory committee meeting in September, Intercept Pharmaceuticals’ bid to win full approval for its liver disease drug Ocaliva has come up short. Intercept on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback